Epigenomics AG. (8/7/17). "Press Release: Epigenomics AG – Notice of Loss Pursuant to § 92 par. 1 AktG".

	Organisation	Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY)
	Group	Epigenomics (Group)
	Organisation 2	Frankfurt Stock Exchange (FSE)
	Group	Deutsche Börse (Group)
	Product	epigenetics / epigenomics
	Product 2	investment banking
	Person	Vogt, Peter (Epigenomics 201601 Investor + Public Relations)

Publication of Inside Information according to Article 17 MAR

The Executive Board of Epigenomics AG (FSE: ECX; OTCQX: EPGNY) notifies that according to its best judgment a cumulative loss of more than half of the nominal share capital of the company has been incurred. This is mainly attributable to budgeted losses from regular business operations.

The Executive Board is actively reviewing different measures to improve the Company’s equity and liquidity.

Pursuant to Sec. 92 par. 1 German Stock Corporation Act (“Aktiengesetz”), a loss amounting to half of the nominal share capital triggers the statutory obligation to summon a general meeting of shareholders without undue delay. The Executive Board will therefore invite to an extraordinary general meeting in due course. In this meeting, the Executive Board will notify the loss of half of the nominal share capital and outline the situation of the company. An invitation including an agenda to the extraordinary general meeting will be provided in due time and form.

Contact:

Epigenomics AG, Investor Relations, Peter Vogt, Geneststrasse 5, 10829 Berlin, Tel +49 (0) 30 24345 386, Fax +49 (0) 30 24345 555, E-Mail: ir@epigenomics.com

Forward-Looking Statements

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Record changed: 2023-06-05